Physician profile
Ravindra Bhati
NPI 1821198912
$4,944.35
in general payments reported to CMS, 2019-2025
22 companies · $322 in 2025
The $322 reported for 2025 was more than what 85% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $325 · 2021: $692 · 2022: $702 · 2023: $1,071 · 2024: $249 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $780.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $670.68 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.57 | 2019-2023 | Jardiance |
| Sunovion Pharmaceuticals INC. | $378.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $374.34 | 2019-2024 | Lokelma |
| Lexicon Pharmaceuticals, INC. | $249.48 | 2023-2024 | Inpefa |
| Pfizer INC. | $229.67 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $148.46 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.34 | 2019 | |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Shire North American Group INC | $124.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.80 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2022 | |
| Scpharmaceuticals INC. | $124.74 | 2025 | |
| Amgen INC. | $124.74 | 2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $124.74 | 2023 | |
| Emd Serono, INC. | $120.00 | 2022 | |
| Gilead Sciences, INC. | $115.83 | 2023 | Epclusa |
| Phathom Pharmaceuticals, INC. | $108.90 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $101.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.18 | 2019-2020 | |
| Mylan Specialty L.P. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravindra Bhati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.